In:
Cancer, Wiley, Vol. 120, No. 12 ( 2014-06-15), p. 1898-1907
Abstract:
The monoclonal antibody 8F1 has been used to determine ERCC1 levels to predict platinum efficacy and as a prognostic marker for the survival of patients with malignancies. The results of the current study demonstrate that 8F1 detects 2 unrelated proteins, ERCC1 and choline phosphate cytidylyltransferase‐α (CCTα), and that CCTα is prognostic for survival in patients with lung and head and neck squamous cell carcinomas.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v120.12
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1